APPLICATIONS PUBLISHED 5 NOVEMBER 2003

Published: 1-Apr-2004

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T+43 1521 260 F+43 1 52126 4492


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T+43 1521 260 F+43 1 52126 4492

  • Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation
    Quark Biotech; Shionogi 1357881*

  • Use of alkylpolyxylosides as emulsifying agents for preparing water-in-oil emulsions
    S.E.P.P.I.C. Societe d'Expolitation de Produits pour les Industries Chimiques 1357894*

  • Vaccine compsn and stabilisation method
    Aventis Pasteur 1357895*

  • Membrane for encapsulation chamber of cells producing at least a biologically active substance and bioartifical organ comprising same
    Association pur les transfert de technologie Du Mans; Universite Catholique de Louvain; Center Europeen D'Etude du Diabete 1357896*

  • Delivery of biologically active agents
    Medical Research Council 1357897*

  • Improved controlled release oral dosage form
    ANDRX Pharmaceuticals 1357898*

  • Oral itraconazole formulations and methods of making the same
    DSM IP Assets 1357899*

  • Process for the preparation of nanoparticles and microparticles by spray freezing into liquid
    Board of Regents, the University of Texas System 1357900*

  • Process
    AstraZeneca 1357901*

  • Therapeutic agents complexed with calcium phosphate and encased by casein
    Biosante Pharmaceuticals 1357902*

  • Stabilised formulations of 6-hydroxy-3-(4- 2-(piperidin-1-yl) ethoxy]-phenoxy)-2-(4-methoxyphenyl) benzo B]thiophene and salts thereof
    Eli Lilly 1357903*

  • Use of pyrazolo [ 4,3-D]pyrimidines
    Merck Patent 1357904*

  • A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease
    Kamm, Michael Albert 1357905*

  • Blockage of calcium channels by phenol derivatives
    B Braun Melsungen 1357906*

  • Method of treating the syndrome of coronary heart disease risk factors in humans
    CPD 1357907*

  • Acyl sulphamides for treatment of obesity, diabetes and lipid disorders
    Merck 1357908*

  • IL-8 receptor antagonists
    SmithKline Beecham Corp 1357909*

  • Method for preventing and treating visceral pain and gastrointestinal disorders
    Warner-Lambert 1357910*

  • Use of betaine in functional products having blood pressure lowering effects
    Finnfeeds Finland 1357911*

  • Photodynamic therapy of occult choroidal neovascularisation linked to age-related macular degeneration
    QLT; Novartis 1357912*

  • Heterocyclic inhibitors of glycine transporter 2
    Telik 1357913*

  • Treatment of PPAR mediated diseases
    SmithKline Beecham Corp 1357914*

  • Pharmaceutical formulation comprising pyrazolo [4,3-D]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists
    Merck Patent 1357915*

  • Two-component anti-emetic compsn dexamethasone and metoclopramide
    Odyssey Pharmaceuticals 1357916*

  • Use of carbohydrates for eliminating intestinal infections in animals
    Suedzucker Aktiengesellschaft Mannheim/Ochsenfurt 1357917*

  • Metabolic controlled fermentation process for carbamoyl tobramycin production
    Biogal Gyogyszergyar 1357918*

  • Therapy-enhancing glucan
    Sloan-Kettering Institute for Cancer Research 1357919*

  • Compsns and methods of tissue superoxygenation
    Hydron Technologies 1357920*

  • Bacterial isolates from organisms that respire at least partially through their skin and biologically active extracts derived therefrom
    Kemin Industries; Plethodon Research 1357921*

  • Cell suspension preparation technique and device
    McComb Foundation 1357922*

  • Herbal compsn for the prevention and treatment of dementia
    Neuromedix; Jung, Jang-Huyn 1357923*

  • Antiviral compsn made from medicinal plants for combating HIV/AIDS
    Gbodossoum, Erick Vidjin' Agnih 1357924*

  • Compsns containing an active fraction isolated from Hedyotis diffusae and methods of use
    Wackycom 1357925*

  • Local use of ethereal oils
    Walther Schoenenberger Pfanzensaftenwerk; Heiss, Markus M; Tarabichi, Anwar 1357926*

  • Cholesterol-lowering agent
    Societe des Produits Nestle 1357927*

  • A novel pharmaceutical compound and methods of making and using same
    New River Pharmaceuticals 1357928*

  • Keratinocyte growth factor-2
    Human Genome Sciences 1357931*

  • Crystal modification of a cyclic depsipeptide having improved strength
    Bayer 1357932*

  • Modified erythropoietin (EPO) with reduced immunogenicity
    Merck 1357933*

  • Modified interleukin-1 receptor antagonist (IL-1RA) with reduced immunogenicity
    Merck Patent 1357934*

  • Method of reducing side effects of chemotherapy in cancer patients
    Sciclone Pharmaceuticals 1357935*

  • Biocatalytic and biomimetic generation of nitric oxide in situ at substrate/blood interface
    The Board of Regents of the University of Michigan 1357936*

  • Use of a botuline toxin to obtain a product to be used in articular pathologies, particularly coxarthritis, epiconylitis and rotator muscle cap pathology
    Universita' Degli Studi di Udine 1357937*

  • Hyperblebbing bacterial strains and use thereof for production of vaccines
    SmithKline Beecham Biologics 1357938*

  • Haemophilus influenza BASB212 polynucleotides, polypeptides and use thereof
    GlaxoSmithKline Biologicals 1357939*

  • Hepatitis B virus treatment
    Stressgen Biotechnologies Inc 1357940*

  • Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
    SmithKline Beecham 1357941*

  • Methods and compsns for treatment of immune dysfunction disorders
    The Lauridsen Group 1357942*

  • Methods and compsns for modulating the immune systems of animals
    The Lauridsen Group 1357943*

  • Perylenequinones for use with immunotherapy agents
    Altachem Pharma 1357944*

  • Method to prevent vision loss
    QLT; Novartis 1357945*

  • Reduced fluence rate PDT
    QLT 1357946*

  • Novel compsns of potassium channel openers and protein kinase C inhibitors and use thereof
    Pharmacia 1357974*

  • Medicament compsns with negligible side-effects containing beta-mimetics
    Boehringer Ingelheim Pharma 1357975*

  • Pharmaceutical compsns having few side-effects
    Boehringer Ingelheim Pharma 1357976*

  • Chromium-containing compsns for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesterolemia
    Nutrition 21 1357977*

  • Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity
    Glaxo Group 1358152*

  • Ophthalmic compsns for treating ocular hypertension
    Merck 1358153*

  • Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases
    Abbott Laboratories 1358154*

  • Aromatic sulphonyl alpha-cycloamino hysroxamates and their use as MMP inhibitors
    Pharmacia 1358155*

  • Benz(G) indoles and their use as SPLA2 inhibitors
    Eli Lilly 1358156*

  • Carbazole derivatives and their use as neuropeptide Y5 receptor ligands
    AstraZeneca 1358157*

  • N-substituted tetrahydropyridines and their use as pesticides
    Syngenta Participations 1358158*

  • 3,4-diaminopyridine tartrate and phosphate, pharmaceutical compsns and uses thereof
    Assistance Publique, Hopitaux de Paris; Guyon, Francois; Pradeau. Dominique; Le Hoang, My Dung; Houri, Jean-Jacques 1358159*

  • Aminal diones as potassium channel openers
    Abbot Laboratories 1358160*

  • N-pyridyl carboxamide derivatives and pharmaceutical compsns containing them
    Amgen 1359161*

  • Dihydroindole and tetrahydroquinoline derivatives
    F Hoffmann-la Roche 1358162*

  • Melancortin receptor agonists
    Eli Lilly 1358163*

  • Method of producing 1-alkyl-3-aryl-5-diflurormethoxy-1H-pyrazoles
    BASF 1358164*

  • Imidazole derivatives
    F Hoffmann-La Roche 1358165*

  • Process for the preparation of triazinylaminostilbene-disulphonic acid compounds
    Ciba Specialty Chemicals Holding 1358166*

  • Novel 2-benzoxazolyl benzene derivatives and their use as UV screening agents
    Roche Vitamins 1358167*

  • Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
    F Hoffmann-La Roche 1358168*

  • Diaminothiazoles and their use as cyclin-dependent kinase
    F Hoffmann-La Roche 1358169*

  • Process for preparing higher primary alkanols
    Cilag 1358170*

  • Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compsns and novel use
    Aventis Pharma 1358171*

  • Amino ceramide-like compounds and therapeutic methods of use
    The Regents of the University of Michigan 1358172*

  • Method for producing optically active, propargylic terminal epoxides
    Forschungszentrum Juelich 1358173*

  • Inhibitors of cruzipain and other cysteine proteases
    Amura Therapeutics 1358174*

  • Phenoxy substituted benzo-condensed heteroaryl derivatives
    Karo Bio 1358175*

  • Inhibitors of cruzipain and other cysteine proteases
    Amura Therapeutics 1358176*

  • Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
    Neurosearch 1358177*

  • Sulphonide lactam inhibitors of factor XA
    Bristol-Myers Squibb 1358178*

  • Synthesis method and intermediates of pyridin-2-yl-methylamine

    Pierre Fabre Medicament 1358179*

  • Naphthostyril derivatives and their use as inhibitors of cyclin-dependent kinases
    F Hoffmann-La Roche 1358180*

  • Substituted pyrrolidines as CCR-3 receptor antagonists
    F Hoffmann-La Roche 1358181*

  • Diazocine derivatives and their use as tryptase inhibitors
    Byk Gulden Lomberg Chemische Fabrik 1358182*

  • Cysteine protease inhibitors
    Medivir 1358183*

  • Substituted alkylamide derivatives and methods of use
    Amgen 1358184*

  • Pyridoarylphenyl oxazolidinone antibacterials and related compounds and methods
    Ortho-McNeil Pharmaceuticals 1358185*

  • Laulimalide derivatives
    Kosan Biosciences 1358186*

  • Naphthyridine derivatives
    Glaxo Group 1358187*

  • Antagonists of MCP-1 function and methods of use thereof
    Telik; Sanwa Kagaku Kenkyusho 1358188*

  • Process for the preparation of a pyrazolo [ 4,3-D]pyrimidine derivative
    Merck Patent 1358189*

  • Amorphous organic 1,3,2-dioxaborine luminophores, method for the production and use thereof
    Siemens 1358190*

    • Companies:
    • Kemin
    See more

    • You may also like

    Applications published 5 December 2007

    Read more

    Trending Articles

    1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
    2. ChargePoint invest in a single-use manufacturing facility to expand product line The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
    3. N4 Pharma and SRI to target and treat previously unreachable human cells The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
    4. Berry Global invests to increase production capacity for healthcare products Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
    5. Innovation in generics: increased efficiency through peptide API synthesis expertise Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues

    Upcoming event

    Cleanroom Conference UK

    22–23 May 2024 | Exhibition | Birmingham, UK     See all

    You may also like

    Applications published 5 December 2007

    APPLICATIONS PUBLISHED 2 MARCH 2005

    The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492

    APPLICATIONS PUBLISHED 26 MAY 2004

    The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492

    Applications Published 4 October 2001

    The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).
    Manufacturing

    Innovation in generics: increased efficiency through peptide API synthesis expertise

    Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
    Regulatory

    Broughton receives flexible scope ISO 17025 accreditation

    New certification allows accreditation without prior approval
    Research & Development

    N4 Pharma and SRI to target and treat previously unreachable human cells

    The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
    Subscribe now